Kelonia develops genetic medicines utilizing its proprietary iGPS® technology for targeted delivery of genetic cargo to specific tissues. The company is advancing its pipeline, including in vivo BCMA CAR-T therapies for hematologic malignancies. This platform aims to efficiently provide genetic medicine solutions across a broad patient population.
Funding
$57.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer and immune disease treatments often lack precision, leading to off-target effects and limited efficacy. Effective therapies are needed to specifically target diseased tissues while minimizing harm to healthy cells.
Solution
Kelonia Therapeutics is developing genetic medicines using its innovative iGPS® technology. This platform leverages lentiviral vector-like particles to enable targeted in vivo gene delivery, directing genetic cargo specifically to the desired tissue. This approach aims to improve the treatment of solid tumors and hematologic cancers by delivering therapeutic genes directly to the affected cells, potentially enhancing efficacy and reducing side effects. The iGPS® technology builds on extensive research and development to efficiently deliver genetic material with precision.
Target Audience
Kelonia Therapeutics' primary target audience includes patients with solid tumors and hematologic cancers, as well as healthcare providers seeking more effective and targeted treatment options.
Features
- iGPS® technology platform for targeted in vivo gene delivery
- Lentiviral vector-like particles for efficient genetic cargo delivery
- Precise targeting of genetic material to specific tissues
- Potential for improved efficacy and reduced side effects in cancer and immune disease treatments